Compounds > bezafibrate
Page last updated: 2024-08-23

bezafibrate and Apolipoprotein C-II Deficiency

bezafibrate has been researched along with Apolipoprotein C-II Deficiency in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abe, M; Fukuda, N; Haketa, A; Hatanaka, Y; Kobayashi, H; Nakamura, Y; Soma, M; Tanaka, S; Tsunemi, A; Ueno, T1
Saito, Y; Yoshida, S1

Other Studies

2 other study(ies) available for bezafibrate and Apolipoprotein C-II Deficiency

ArticleYear
Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
    Internal medicine (Tokyo, Japan), 2019, Jan-15, Volume: 58, Issue:2

    Topics: Adult; Age of Onset; Bezafibrate; Diabetes Complications; Ezetimibe; Genetic Variation; Heterozygote; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoprotein Lipase; Male

2019
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1989, Volume: 78, Issue:10

    Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Naphthalenes; Pravastatin; Probucol; Triglycerides

1989